NMS-03305293 is named as an intervention in 3 current clinical trials in our USA register. 2 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Nerviano Medical Sciences. The most-studied condition is Small Cell Lung Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
NCT06930755 · ClinicalTrials.gov ↗ · Ovarian Cancer
|
Phase 1 | Recruiting | Nerviano Medical Sciences | USA |
|
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
NCT06931626 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
|
Phase 1 | Recruiting | Nerviano Medical Sciences | USA |
|
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
NCT04910022 · ClinicalTrials.gov ↗ · Glioblastoma, Diffuse Glioma
|
Phase 1/2 | Active, closed | Nerviano Medical Sciences | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Nerviano Medical Sciences | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA register name NMS-03305293 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Nerviano Medical Sciences. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NMS-03305293 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NMS-03305293 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NMS-03305293 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.